Suppr超能文献

依那普利或替米沙坦治疗的蛋白尿性慢性肾病犬的血清对称二甲基精氨酸浓度

Serum symmetric dimethylarginine concentrations in enalapril- or telmisartan-treated dogs with proteinuric chronic kidney disease.

作者信息

Nasr Amirah, Lourenço Bianca N, Coleman Amanda E, Bartges Joseph W

机构信息

Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.

出版信息

Front Vet Sci. 2024 Dec 6;11:1471606. doi: 10.3389/fvets.2024.1471606. eCollection 2024.

Abstract

INTRODUCTION

Renin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD). RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated. The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy.

METHODS

This retrospective study used banked samples from 29 dogs with proteinuric CKD treated with enalapril (0.5 mg/kg PO q12h;  = 16) or telmisartan (1 mg/kg PO q24h;  = 13) alone ( = 22) or in combination with amlodipine if severely hypertensive ( = 7). Serum SDMA, creatinine, and urea nitrogen (SUN) concentrations were measured before and 7 and 30 days after starting RAASi. Percentage and absolute changes in these biomarkers were calculated for each dog and time point. A linear mixed model was used to test whether changes significantly differed from zero ( < 0.05).

RESULTS

Overall, mean ± SEM Day 7 and 30 percentage change in SDMA were  - 4.8 ± 3.6% and  - 3.2 ± 3.4%, respectively; in creatinine were 7.4 ± 3.3% and 3.0 ± 3.1%, respectively; and in SUN were 22.1 ± 6.8% and 16.7 ± 6.2%, respectively. Mean changes varied according to whether all dogs, those on RAASi alone, or those co-treated with amlodipine were evaluated. In dogs receiving RAASi alone, at day 7, there were significant mean percentual increases in creatinine (9%;  = 0.023) and SUN (23%;  = 0.005), but SDMA was unchanged. In dogs co-treated with amlodipine, a significant absolute decrease in mean SDMA (-2.29 μg/dL;  = 0.026) occurred at days 7 and 30, while mean creatinine was unchanged and mean SUN increased.

DISCUSSION

Proteinuric dogs receiving RAASi had low-magnitude changes in serum SDMA and creatinine, and moderate-magnitude changes in SUN concentrations. The direction of change in SDMA did not consistently match that of creatinine and SUN.

摘要

引言

肾素-血管紧张素-醛固酮系统抑制(RAASi)可降低肾小球内压力,是治疗蛋白尿性慢性肾脏病(CKD)犬的标准疗法。RAASi可急性降低肾小球滤过率(GFR);然而,其对犬GFR标志物血清对称二甲基精氨酸(SDMA)浓度的影响尚未得到具体评估。本研究的目的是评估接受RAASi治疗的蛋白尿性CKD犬血清SDMA浓度相对于治疗前值的变化。

方法

这项回顾性研究使用了29只蛋白尿性CKD犬的储存样本,这些犬单独接受依那普利(0.5mg/kg口服,每12小时一次;n = 16)或替米沙坦(1mg/kg口服,每24小时一次;n = 13)治疗(n = 22),如果严重高血压则联合氨氯地平治疗(n = 7)。在开始RAASi治疗前以及治疗后7天和30天测量血清SDMA、肌酐和尿素氮(SUN)浓度。计算每只犬和每个时间点这些生物标志物的百分比和绝对变化。使用线性混合模型测试变化是否显著不同于零(P < 0.05)。

结果

总体而言,SDMA在第7天和第30天的平均±SEM百分比变化分别为-4.8±3.6%和-3.2±3.4%;肌酐分别为7.4±3.3%和3.0±3.1%;SUN分别为22.1±6.8%和16.7±6.2%。平均变化根据评估的是所有犬、单独接受RAASi治疗的犬还是联合氨氯地平治疗的犬而有所不同。在单独接受RAASi治疗的犬中,第7天时,肌酐(9%;P = 0.023)和SUN(23%;P = 0.005)有显著的平均百分比增加,但SDMA没有变化。在联合氨氯地平治疗的犬中,第7天和第30天时平均SDMA有显著的绝对下降(-2.29μg/dL;P = 0.026),而平均肌酐没有变化,平均SUN增加。

讨论

接受RAASi治疗的蛋白尿性犬血清SDMA和肌酐有小幅度变化,SUN浓度有中等幅度变化。SDMA的变化方向与肌酐和SUN的变化方向并不一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7934/11660089/a0bb35b63b13/fvets-11-1471606-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验